2000-2004年在南京大学本科学习获得学士学位；2004-2009年在南京大学师从徐强教授并获得博士学位；2009-2011年在美国Baylor College of Medicine进行博士后培训；2011-2015年在康奈尔大学Weill医学院附属Methodist医院任助理研究员；2015年3月起获聘中山大学中山医学院教授、博导；2021年1月起获聘广东省人民医院研究员、博导。
Ph.D.博士，研究员，博士生导师，第十一批国家“千人计划青年项目”入选者。 承担各级科研基金10余项，包括：国家千人计划启动经费1项（已结题），国家自然科学基金面上项目3项（已结题1项），国家重点研发计划“干细胞研究专项”课题1项，广东省千人计划配套经费1项（已结题）等。作为项目核心成员参与广东省珠江人才创新创业团队1项、广东省自然科学基金创新团队项目1项。 代表性论文（*标注通讯作者）： 1. Jmjd3 Inhibits Reprogramming by Upregulating Expression of INK4a/Arf and Targeting PHF20 for Ubiquitination. Zhao W, Li Q, Ayers S, Gu Y, Shi Z, Zhu Q, Chen Y, Wang HY, Wang RF*. Cell. 2013 Feb 28;152(5):1037-50. IF：41.582 2. Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma. Lu B#, Zou C#, Yang M, He Y, He J, Zhang C, Chen S, Yu J, Liu KY, Cao Q, and Zhao W*. Adv Sci. 2021 Aug 25;e2101895. IF：16.806 3. Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma. Li FX#, Chen SY#, Yu JM, Gao ZX, Sun ZY, Yi Y, Long T, Zhang CX, Li YZ, Pan YM, Qin CY, Long WY*, Liu Q*, Zhao W*. Clin Transl Med. 2021.11:e553. IF：11.429 4. Nanoparticle Enhanced Combination Therapy for Stem-like Progenitors Defined by Single-Cell Transcriptomics in Chemotherapy-Resistant Osteosarcoma. Wang L#, Huang X#, You X#, Yi T, Lu B, Liu J, Lu G, Ma M, Zou C, Wu J*, and Zhao W*. Signal Transduct Target Ther, 2020 Sep 25;5(1):196. IF：18.187 5. Interplay of m6A and H3K27 trimethylation restrains inflammation during bacterial infection. Wu C#, Chen W#, He J#, Jin S, Liu Y, Yi Y, Gao Z, Yang J, Yang J*, Cui J*, and Zhao W*. Sci Adv. 2020 Aug 19:Vol. 6, no. 34, eaba0647. IF：14.136 6. Targeting Super-Enhancers via Nanoparticle-facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Huang CS#, You X#, Dai C, Xu QC, Li F, Wang L, Huang XT, Wang JQ, Li SJ, Gao Z, Wu J*, Yin XY*, and Zhao W*. Adv Sci. 2020 Feb 16;7(7):1902926. IF：16.806 7. N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma. Li F#, Yi Y#, Miao Y#, Long W, Long T, Chen S, Cheng W, Zou C, Zheng Y, Wu X, Ding J, Zhu K, Chen D, Xu Q, Wang J, Liu Q, Zhi F, Ren J, Cao Q*, Zhao W*. Cancer Res. 2019 Sep 17. IF：12.701 8. MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway. Li JH#, Zhu XX#, Li FX, Huang CS, Huang XT, Wang JQ, Gao ZX, Li SJ, Xu QC, Zhao W*, Yin XY*. J Exp Clin Cancer Res. 2019 Nov 27;38(1):476. IF：11.161 9. Nanomaterial-Facilitated Cyclin Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction. Huang CS, Xu QC, Dai CL, Wang LY, Tien YC, Li FX, Su Q, Huang XT, Wu J, Zhao W*, Yin XY. ACS Nano 2021 Sep 28;15(9):14744-14755. IF：15.881 10. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner. Xu QC#, Tien YC#, Shi YH#, Chen S, Zhu YQ, Huang XT, Huang CS, Zhao W*, Yin XY*. Oncogene. 2022 Jan 29. doi: 10.1038/s41388-022-02185-1. Online ahead of print. IF：9.867
